AXSM
Price
$116.62
Change
-$0.00 (-0.00%)
Updated
Sep 18, 12:12 PM (EDT)
Capitalization
5.69B
53 days until earnings call
XENE
Price
$37.45
Change
+$0.75 (+2.04%)
Updated
Sep 18, 02:07 PM (EDT)
Capitalization
2.75B
48 days until earnings call
Interact to see
Advertisement

AXSM vs XENE

Header iconAXSM vs XENE Comparison
Open Charts AXSM vs XENEBanner chart's image
Axsome Therapeutics
Price$116.62
Change-$0.00 (-0.00%)
Volume$400
Capitalization5.69B
Xenon Pharmaceuticals
Price$37.45
Change+$0.75 (+2.04%)
Volume$600
Capitalization2.75B
AXSM vs XENE Comparison Chart in %
Loading...
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AXSM vs. XENE commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXSM is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (AXSM: $116.62 vs. XENE: $36.68)
Brand notoriety: AXSM and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXSM: 100% vs. XENE: 109%
Market capitalization -- AXSM: $5.69B vs. XENE: $2.75B
AXSM [@Biotechnology] is valued at $5.69B. XENE’s [@Biotechnology] market capitalization is $2.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXSM’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • AXSM’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than AXSM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXSM’s TA Score shows that 6 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).

  • AXSM’s TA Score: 6 bullish, 4 bearish.
  • XENE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AXSM is a better buy in the short-term than XENE.

Price Growth

AXSM (@Biotechnology) experienced а -6.04% price change this week, while XENE (@Biotechnology) price change was -1.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.40%. For the same industry, the average monthly price growth was +12.19%, and the average quarterly price growth was +39.12%.

Reported Earning Dates

AXSM is expected to report earnings on Nov 10, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXSM($5.69B) has a higher market cap than XENE($2.75B). AXSM YTD gains are higher at: 37.832 vs. XENE (-6.429). AXSM has higher annual earnings (EBITDA): -230.81M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. AXSM (303M). XENE has less debt than AXSM: XENE (8.72M) vs AXSM (217M). AXSM has higher revenues than XENE: AXSM (495M) vs XENE (7.5M).
AXSMXENEAXSM / XENE
Capitalization5.69B2.75B207%
EBITDA-230.81M-315.5M73%
Gain YTD37.832-6.429-589%
P/E RatioN/AN/A-
Revenue495M7.5M6,600%
Total Cash303M488M62%
Total Debt217M8.72M2,490%
FUNDAMENTALS RATINGS
AXSM vs XENE: Fundamental Ratings
AXSM
XENE
OUTLOOK RATING
1..100
8166
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
6340
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
5159
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
3975

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (74) in the Biotechnology industry is in the same range as AXSM (90) in the Pharmaceuticals Other industry. This means that XENE’s stock grew similarly to AXSM’s over the last 12 months.

XENE's Profit vs Risk Rating (40) in the Biotechnology industry is in the same range as AXSM (63) in the Pharmaceuticals Other industry. This means that XENE’s stock grew similarly to AXSM’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that XENE’s stock grew similarly to AXSM’s over the last 12 months.

AXSM's Price Growth Rating (51) in the Pharmaceuticals Other industry is in the same range as XENE (59) in the Biotechnology industry. This means that AXSM’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for AXSM (100) in the Pharmaceuticals Other industry. This means that XENE’s stock grew significantly faster than AXSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXSMXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 17 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDGSX37.36N/A
N/A
Hartford Dividend and Growth R4
ISIPX19.59N/A
N/A
Voya US Stock Index Port S2
MITEX17.56N/A
N/A
Matthews Asia Innovators Institutional
TEUIX26.77N/A
N/A
T. Rowe Price European Stock I
JGQYX18.29N/A
N/A
Jensen Global Quality Growth Y

AXSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with CRNX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXSM
1D Price
Change %
AXSM100%
+2.21%
CRNX - AXSM
40%
Loosely correlated
+0.29%
ALNY - AXSM
38%
Loosely correlated
-2.06%
XENE - AXSM
36%
Loosely correlated
+2.86%
VANI - AXSM
36%
Loosely correlated
+20.66%
PLRX - AXSM
35%
Loosely correlated
-4.25%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+2.86%
IDYA - XENE
57%
Loosely correlated
-1.13%
CRNX - XENE
55%
Loosely correlated
+0.29%
NRIX - XENE
52%
Loosely correlated
+1.54%
ATXS - XENE
52%
Loosely correlated
+1.79%
OCUL - XENE
51%
Loosely correlated
-2.17%
More